VGI Health Technology Limited (NSX:VTL), is pleased to announce that its wholly-owned subsidiary, Invictus Biotechnology Pty Ltd, has lodged a new PCT Patent Application titled: 'Transmucosal delivery of tocotrienols' (PCT patent application number: PCT/AU2021/051449).
In September 2015, a Phase Ia clinical study on IVB001 had positive topline data where all primary endpoints were achieved, including: confirmation of the bioavailability of the compound, with good plasma levels, dose relationship and duration of plasma levels achieved.
Ladies and gentlemen, I am pleased to report that BTC Health Limited (ASX:BTC) has achieved a number of milestones over the past 12 months, including a greater penetration of our products within hospitals.
iQX Limited (NSX:IQX), on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), in which IQX holds 19% equity position, today announced the successful completion of a clinical validation study showcasing the efficacy of its rapid SARS-Cov-2 Antibody test.
iQX Limited (NSX:IQX) is pleased to announce that OncoTEX Inc has received licensing for a gold compound platform technology that induces the body's immune system to destroy cancer cells.
VGI Health Technology Limited (NSX:VTL) is pleased to announce that the Japanese Patent Office intends to grant a patent for the Transmucosal Delivery of Tocotrienols.
2021 has been a significant year for Anatara Lifesciences Limited (ASX:ANR), as we made steps towards progressing our human health products towards clinical trials, successfully completed animal health studies and progressed licensing discussions.
